• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket

    1/18/23 7:50:09 AM ET
    $APTX
    $ATER
    $ATXI
    $BTCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Home Furnishings
    Consumer Discretionary
    Get the next $APTX alert in real time by email

    Gainers

    • Siyata Mobile Inc. (NASDAQ:SYTA) rose 41.5% to $0.3255 in pre-market trading after gaining 8% on Tuesday.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) rose 26.4% to $0.60 in pre-market trading after the company announced strategic agreement with the City of Huanggang and signed a new shareholder agreement with FF Global Partners.
    • Celyad Oncology SA (NASDAQ:CYAD) shares rose 26.4% to $2.41 in pre-market trading after jumping 138% on Tuesday. Celyad Oncology recently issued an update on its Celyad 2.0 business strategy, which has been adopted and implemented over the last few months.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) shares rose 15.1% to $2.29 in pre-market trading after climbing over 60% on Tuesday. Avenue Therapeutics, during November, posted a Q3 loss of $0.45 per share.
    • PaxMedica, Inc. (NASDAQ:PXMD) shares rose 14% to $3.34 in pre-market trading after gaining around 17% on Tuesday.
    • AVITA Medical, Inc. (NASDAQ:RCEL) rose 12.4% to $9.05 in pre-market trading after gaining around 7% on Tuesday. AVITA Medical, last month, submitted FDA PMA application to expand indication to vitiligo.
    • Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) rose 10.6% to $1.25 in pre-market trading. Citius Pharmaceuticals, last month, reported FY22 earnings results.
    • Aterian, Inc. (NASDAQ:ATER) rose 9.8% to $1.46 in pre-market trading. Aterian shares gained 37% on Tuesday after the company issued Q4 revenue guidance above analyst estimates.
    • Healthcare Triangle, Inc. (NASDAQ:HCTI) rose 8.7% to $0.25 in pre-market trading. Healthcare Triangle, during November, posted a Q3 loss of $0.06 per share.
    • Moderna, Inc. (NASDAQ:MRNA) rose 6.5% to $203.00 in pre-market trading after the company's syncytial virus vaccine candidate met its primary endpoint in a Phase 3 trial.

     

    Losers

    • Arcimoto, Inc. (NASDAQ:FUV) fell 44.4% to $3.40 in pre-market trading after the company reported a proposed public offering.
    • IronNet, Inc. (NYSE:IRNT) shares fell 11.8% to $0.3601 in pre-market trading. IronNet, last month, announced receipt of noncompliance letter from NYSE.
    • The Very Good Food Company Inc. (NASDAQ:VGFC) fell 10.5% to $0.06 in pre-market trading. The Very Good Food Company announced the receivership order, suspension of trading and board member resignation.
    • Edesa Biotech, Inc. (NASDAQ:EDSA) fell 8.9% to $1.33 in pre-market trading. Edesa Biotech shares dropped around 42% on Tuesday after the company reported topline Phase 2b results for its dermatology drug.
    • Hour Loop, Inc. (NASDAQ:HOUR) shares fell 8.7% to $2.61 in pre-market trading after gaining over 5% on Tuesday.
    • SOS Limited (NYSE:SOS) fell 7.7% to $7.56 in pre-market after jumping around 20% on Tuesday.
    • BIT Mining Limited (NYSE:BTCM) shares dropped 6.8% to $4.06 in pre-market trading. BIT Mining shares jumped 42% on Tuesday after the company announced the launch of a new energy efficient LiteCoin/DogeCoin Miner, LD3.
    • Calyxt, Inc. (NASDAQ:CLXT) fell 6.3% to $0.3310 in pre-market trading. Calyxt shares jumped over 90% on Tuesday after the company and Cibus announced a definitive merger agreement.
    • Aptinyx Inc. (NASDAQ:APTX) fell 6.3% to $0.46 in pre-market trading. Aptinyx , during November, posted a Q3 loss of $0.23 per share.
    • MultiMetaVerse Holdings Limited (NASDAQ:MMV) fell 5.5% to $2.71 in pre-market trading. MultiMetaVerse recently announced a letter of intent to acquire a majority equity stake in Taomee.
    Get the next $APTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APTX
    $ATER
    $ATXI
    $BTCM

    CompanyDatePrice TargetRatingAnalyst
    Avita Medical Inc.
    $RCEL
    3/5/2026$10.00Outperform
    Northland Capital
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Avita Medical Inc.
    $RCEL
    11/20/2025Sell → Neutral
    BTIG Research
    Avita Medical Inc.
    $RCEL
    8/8/2025$3.00Neutral → Sell
    BTIG Research
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $APTX
    $ATER
    $ATXI
    $BTCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital initiated coverage on Avita Medical with a new price target

    Northland Capital initiated coverage of Avita Medical with a rating of Outperform and set a new price target of $10.00

    3/5/26 8:30:26 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Moderna with a new price target

    UBS resumed coverage of Moderna with a rating of Neutral and set a new price target of $34.00

    1/7/26 9:12:19 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    SEC Filings

    View All

    Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

    4/24/26 5:00:16 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Citius Pharmaceuticals Inc.

    424B5 - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

    4/24/26 9:24:38 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Avita Medical Inc.

    DEF 14A - AVITA Medical, Inc. (0001762303) (Filer)

    4/22/26 4:30:16 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nijhawan Pardeep bought $6,599 worth of shares (1,000 units at $6.60), increasing direct ownership by 0.16% to 628,813 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/10/26 5:02:16 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $39,000 worth of shares (10,000 units at $3.90) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/6/26 5:01:15 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $42,560 worth of shares (10,000 units at $4.26) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/5/26 5:01:11 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $APTX
    $ATER
    $ATXI
    $BTCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Nijhawan Pardeep

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    4/10/26 5:02:20 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bui Hillary Hui-Chong

    4 - Hour Loop, Inc (0001874875) (Issuer)

    4/7/26 4:05:06 PM ET
    $HOUR
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 4 filed by Gao Minghui

    4 - Hour Loop, Inc (0001874875) (Issuer)

    4/7/26 4:05:08 PM ET
    $HOUR
    Catalog/Specialty Distribution
    Consumer Discretionary

    $APTX
    $ATER
    $ATXI
    $BTCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

    CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 5,076,143 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.985 per share (or pre-funded warrant in lieu thereof). In a concurrent private placement, the Company issued unregistered warrants to purchase up to 5,076,143 shares of common stock at an exe

    4/24/26 4:30:00 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

    CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 5,076,143 shares of its common stock  (or pre-funded warrants in lieu thereof) at a purchase price of $0.985 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,076,143 shares of comm

    4/24/26 8:00:00 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AVITA Medical to Announce First Quarter 2026 Financial Results

    VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. First Quarter 2026 Webcast and Conference Call InformationTo listen to the conference call webcast, please register and join using the following link: https://edge.media-serve

    4/23/26 4:10:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    Financials

    Live finance-specific insights

    View All

    AVITA Medical to Announce First Quarter 2026 Financial Results

    VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. First Quarter 2026 Webcast and Conference Call InformationTo listen to the conference call webcast, please register and join using the following link: https://edge.media-serve

    4/23/26 4:10:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Aterian Provides Update on Strategic Alternatives Process

    SUMMIT, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Aterian, Inc. (NASDAQ:ATER) ("Aterian" or the "Company"), a consumer products company, today provided the following update on its previously announced Strategic Alternative Process. "Our Strategic Alternative Process is progressing well since our first announcement in December 2025. We continue to engage in constructive discussions regarding potential strategic alternatives and are making progress in evaluating opportunities. We are guided in this initiative by our continued belief that our current market valuation simply does not reflect the sum-of-the-parts value of our brand portfolio. We continue to approach this review thoughtfully and

    3/23/26 8:30:00 AM ET
    $ATER
    Home Furnishings
    Consumer Discretionary

    AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

    VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights and Recent Business Updates Total revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering impact of reimbursement headwinds throughout 2025.Gross profit margin of 81.2%, reflecting product mix and inventory-related adjustments.Net use of cash improved for the second consecutive quarter t

    2/12/26 4:01:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $APTX
    $ATER
    $ATXI
    $BTCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

    SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

    11/27/24 4:05:31 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Siyata Mobile Inc.

    SC 13G/A - Siyata Mobile Inc. (0001649009) (Subject)

    11/14/24 7:28:44 PM ET
    $SYTA
    Telecommunications Equipment
    Telecommunications

    $APTX
    $ATER
    $ATXI
    $BTCM
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AVITA Medical Announces Changes to its Board of Directors

    Veteran healthcare executive Joe Woody joins the BoardLou Panaccio retires after over a decade of service VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025. "We are pleased to welcome Joe to the Board. His extensive track record leading global med-tech companies and driving commercial excellence will be invaluable as we continue to scale AVITA Medical's growth," said Cary Vance, Interim CEO of

    1/5/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SOLAI Limited Joins RWA Alliance as a Founding Member to Advance Tokenization of Green Energy Assets

    AKRON, Ohio, Oct. 21, 2025 /PRNewswire/ -- SOLAI Limited (NYSE: SLAI) ("SOLAI" or the "Company"), a leading technology-driven cryptocurrency infrastructure company (previously known as "BIT Mining"), today announced that it has officially joined the Real-World Assets (RWA) Alliance as one of its founding members. The RWA Alliance is dedicated to solving critical industry pain points – such as asset liquidity and opaque valuation – by promoting the tokenization of real-world assets. By leveraging blockchain technology to standardize, divide, and bring transparency to physical assets, the Alliance aims to open up new pathways for the digital transformation of the green energy sector through r

    10/21/25 6:00:00 AM ET
    $BTCM
    EDP Services
    Technology